Floatz logo

Mitoxantrone

Acute Myeloblastic Leukemia Without Maturation

Stanford UniversitySmall moleculePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Acute Myeloblastic Leukemia Without Maturation cohort.

Asset / SponsorPhaseRating
Etoposide
Stanford University
Phase 3BBB
Cytarabine
Northwestern University
Phase 3BBB
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB
Idarubicin
Bruno C. Medeiros
Phase 3BBB

View all 50 →

Same molecule, other indications

Mitoxantrone is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative · Phase 4
77 / 100
View asset →
acute monocytic leukemiaActive
BBB
Indicative · Phase 2/3
74 / 100
View asset →
myeloid neoplasmActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →